NP1
NP1 is a NOTA-chelated linear precursor based on the ROR1-targeting peptide. After labeling with [18F]AlF, NP1 yields [18F]AlF-NP1, a PET imaging probe with excellent ROR1 specificity (KD = 141.7 nM), rapid tumor uptake and high target-to-background ratio, which is suitable for non-invasive visualization of various ROR1-overexpressing tumors.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C96H132TN26O32
- Peso molecular:2165.25
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Radionuclide-Drug Conjugates (RDCs)
More
Actividad biológica
|
ROR-α 141.7 nM (Kd) |
[18F]AlF-NP1 (3.125-400 nM; 10-60 min) exhibits specific and high uptake in ROR1-positive MC38 cells, with a KD value of 141.7 nM. It also shows evident uptake in B16F10, A549 and HepG2 cells, and the uptake level in MC38 cells is significantly higher than that in B16F10 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
[18F]AlF-NP1 (3.7 MBq; intravenous injection; single administration) exhibits measurable tumor uptake and target-to-nontarget ratios in A549 lung cancer xenograft mice[1].
[18F]AlF-NP1 (3.7 MBq; intravenous injection; single administration) exhibits high specific tumor uptake and desirable target-to-nontarget ratios in MC38 colon cancer xenograft mice, and is cleared via the kidneys[1].
[18F]AlF-NP1 (3.7 MBq; intravenous injection; single administration) exhibits specific, measurable tumor uptake and target-to-nontarget ratios in B16F10 melanoma allograft mice[1].
[18F]AlF-NP1 (7.4 MBq; intravenous injection; single administration) exhibits renal clearance properties in healthy C57BL/6 mice, with extremely low uptake in other normal tissues[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 6-8 weeks old, subcutaneous xenograft via HepG2 cell injection)[1]
-
Dosage:3.7 MBq
-
Administration:i.v.; single dose
-
Result:Reached ~0.6% ID/g tumor uptake at 30 minutes postinjection.
Achieved ~4 tumor-to-muscle ratio at 30 minutes postinjection.
Achieved ~0.1 tumor-to-kidney ratio at 30 minutes postinjection.
-
Animal Model:BALB/c nude (male, 6-8 weeks old, subcutaneous xenograft via A549 cell injection)[1]
-
Dosage:3.7 MBq
-
Administration:i.v.; single dose
-
Result:Reached ~0.5% ID/g tumor uptake at 30 minutes postinjection.
Achieved ~5 tumor-to-muscle ratio at 30 minutes postinjection.
Achieved ~0.05 tumor-to-kidney ratio at 30 minutes postinjection.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, subcutaneous allograft via MC38 cell injection)[1]
-
Dosage:3.7 MBq; 3.7 MBq plus 100 μg/mouse PR7 (blocking studies)
-
Administration:i.v.; single dose
-
Result:Reached 2.89% ID/g tumor uptake at 30 minutes postinjection.
Reached 1.32% ID/g tumor uptake at 60 minutes postinjection.
Achieved 2.62 tumor-to-muscle ratio at 60 minutes postinjection.
Reached 27.27% ID/g renal uptake at 30 minutes postinjection.
Reached 17.74% ID/g renal uptake at 60 minutes postinjection.
Reduced tumor uptake significantly when blocked with PR7.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, subcutaneous allograft via B16F10 cell injection)[1]
-
Dosage:3.7 MBq; 3.7 MBq plus 100 μg/mouse PR7 (blocking studies)
-
Administration:i.v.; single dose
-
Result:Reached ~0.6% ID/g tumor uptake at 30 minutes postinjection.
Achieved ~3 tumor-to-muscle ratio at 30 minutes postinjection.
Achieved ~0.05 tumor-to-kidney ratio at 30 minutes postinjection.
Reduced tumor uptake significantly when blocked with PR7.
-
Animal Model:C57BL/6 (male, 6-8 weeks old, normal healthy)[1]
-
Dosage:7.4 MBq
-
Administration:i.v.; single dose
-
Result:Showed high accumulation in kidneys at 30 and 60 minutes postinjection.
Exhibited extremely low radioactivity in all other organs at 30 and 60 minutes postinjection.
Chemical Information
-
Peso molecular 2165.25
-
Fòrmula C96H132TN26O32
-
Sequence
NOTA-Ser-Asp-Ile-Asn-Asp-Arg-Gln-Ile-Pro-Gly-Tyr-Ser-Thr-Tyr-Trp-Gly-Asp-Phe-NH2
-
Sequence Shortening
NOTA-SDINDRQIPGYSTYWGDF-NH2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NP1 Related Classifications
HY-P11859 Related Classifications
Powered by Bioz